IngredientsSceletium refers principally to Sceletium tortuosum (L.) N.E.Br., a perennial succulent plant in the family Aizoaceae (formerly placed in Mesembryanthemaceae). Known locally as kanna — a name derived from the plant's Khoekhoe name — or alternatively kougoed, an Afrikaans term meaning "chewable thing," the plant is native to the Cape Provinces of South Africa, and the name originally referred to the fermented preparation that was chewed by the indigenous Khoisan peoples for its medical and psychoactive effects.
The accepted scientific name is Mesembryanthemum tortuosum L. (synonym: Sceletium tortuosum (L.) N.E.Br.), and these two names are botanical synonyms for the same species. It is a succulent plant that belongs to the family Mesembryanthemaceae, indigenous to South Africa, especially in Namaqualand, where the plant is utilized regularly for its medicinal and psychoactive properties.
The genus Sceletium, classified under the Aizoaceae family, is indigenous to the Western, Eastern, and Northern Cape province of South Africa. There are currently eight reported species divided into two main "types," with five species in the tortuosum type and three in the emarcidum type. Only two species in the genus — S. tortuosum and S. crassicaule — produce the four important mesembrine-type alkaloids responsible for their psychoactive properties. In general, mesembrine-type alkaloids such as mesembrenol, Δ7mesembrenone, mesembranol, mesembrenone, mesembrine, and epimesembranol, as well as some non-mesembrine types such as Sceletium A4, tortuosamine, and joubertiamine, occur in the tortuosum type; the emarcidum type is devoid of alkaloids.
Sceletium tortuosum is typically available commercially as a tincture, tablet, or capsule in unit doses of 50 to 200 mg of the dried, milled herbal material. Several standardized proprietary extracts have been developed for clinical research and supplementation:
The active ingredient of Zembrin is a standardized and characterized aqueous ethanolic (purified water 30% V/V and ethanol 70% V/V, spray-dried onto a maltodextrin carrier) extract of the above-ground material of a cultivated traditionally used selection of the South African plant S. tortuosum.
Plants of the genus Sceletium have likely been used for millennia by San and Khoi peoples as masticatories and traditional medicines for thirst, hunger, fatigue, and social and spiritual purposes; this knowledge from oral tradition of how it was used has declined over the past three centuries due to colonization, conflict, and cultural disruption.
Sceletium tortuosum is a little succulent plant that grows in the semi-arid Karoo and Namaqualand regions of South Africa. It has a long history of traditional use among the hunter-gatherers of the region. The plant, known as kanna or kougoed by the San and Khoikhoi people, was mainly chewed or smoked to stay alert and suppress appetite during long hunts. The San were traditionally hunter-gatherers, while the Khoikhoi were pastoralists who herded livestock. The name kanna (meaning "eland" in the click language of the San), has a symbolic reference to this large antelope, as the "trance animal," which was called upon during religious and spiritual gatherings. Kougoed is Afrikaans for "something to chew."
These communities traditionally chewed the fresh or dried leaves and stems of the plant to induce euphoria, alleviate stress, and suppress hunger and thirst, particularly during long hunts or periods of scarcity in arid environments. Early ethnographic accounts from the 17th century, such as those by Simon van der Stel in 1685, document the Namaqua people — related to the Khoikhoi — gathering and chewing the plant throughout the day for these effects, highlighting its role in daily survival and well-being.
Indigenous healers of the San and Khoikhoi tribes fermented the plant into kougoed, meaning "chewable thing" in Afrikaans. This preparation was chewed, smoked, or inhaled as snuff to induce relaxation, euphoria, and mental clarity. In addition to its common use as a masticatory and as a tea, the aerial parts of Sceletium tortuosum also are used for medicinal purposes, especially for gastrointestinal ailments and respiratory conditions.
Traditionally, this medicinal plant is mainly masticated or smoked and used for the relief of toothache, abdominal pain, as a mood-elevator, analgesic, hypnotic, anxiolytic, thirst and hunger suppressant, and for its intoxicating/euphoric effects. Dried Sceletium tortuosum leaves are used by the San to treat colic in infants, to improve bowel regularity, and to treat abdominal cramps. Interestingly, Sceletium tortuosum has been used by traditional healers to combat addictions and to wean alcoholics off alcohol.
The first written account of its use dates to 1662, recorded by Jan van Riebeeck. The plant has a long history of traditional use by San and Khoikhoi people as a masticatory and medicine, and was later used by colonial farmers as a psychotropic in tincture form (Pappe, 1868). European records from the 18th century describe how the Khoikhoi used Sceletium to "quiet the mind" and relieve thirst during long journeys (Thunberg, 1773). Even early Dutch settlers in South Africa recognized its anxiolytic potential, using it as a natural remedy for anxiety and low mood. However, colonial disruption and the loss of indigenous knowledge led to a decline in its use.
Sceletium plant species that contain alkaloids are claimed to have mood elevation and anti-anxiety properties, especially after the plant material has been fermented. The fermented preparation is locally known as "kougoed" or "channa" and has been emphasized for its increased potency. Although unfermented preparations contain more alkaloids, traditional fermentation enhances psychoactivity by transforming mesembrine into delta-7 mesembrenone, reducing mesembrine content and harmful oxalates. Research has investigated the precise role of fermentation: the essential step in the production of kougoed may not be entirely due to "fermentation" but that crushing the plant material and consequent mixing of cellular material may also be equally necessary. Based on these results, it was suggested that simply crushing and drying at 80°C may be a quick alternative method to modify the alkaloid content.
A study by Patnala and Kanfer (2009) found that the initial fermentation study showed transformation of mesembrine to Δ7mesembrenone, where the content of the former decreased from a concentration of 1.33% to 0.05% whilst the latter increased from below its limit of quantitation to 0.11% on the 10th day.
Twenty-five alkaloids belonging to four structural classes — mesembrine, Sceletium A4, joubertiamine, and tortuosamine — have been identified from S. tortuosum, of which the mesembrine class is predominant. The plant contains more than 25 alkaloids, with mesembrine-type alkaloids predominating.
The primary alkaloids of pharmacological interest include:
The four active alkaloids — mesembrenone, mesembrenol, mesembranol, and mesembrine — are quantified by high-pressure liquid chromatography (HPLC) analysis against validated analytical reference standards.
The alkaloids responsible for psychoactive, sedative, and euphoric properties — principally mesembrine and mesembrenone — may vary in concentration within individual plants depending on their chemotype and degree of exposure to environmental stress. The amount of active compounds in the plant appears to vary by season and locality.
The mechanisms of action on the central nervous system (CNS) of a standardized extract of S. tortuosum (Zembrin) were identified as comprising blockade of the serotonin (5-HT) transporter and selective inhibition of the phosphodiesterase-4 (PDE4) enzyme. The plant extract was reported to be a potent blocker in 5-HT transporter binding assays (with an IC50 value of 4.3 μg/mL) and exhibited high inhibitory effects on PDE4 with an IC50 value of 8.5 μg/mL.
Mesembrine was the most active alkaloid against the 5-HT transporter (Ki 1.4 nM), while mesembrenone was active against the 5-HT transporter and PDE4 (IC50 values <1 μM).
Mesembrine hydrochloride is an inhibitor of phosphodiesterase type 4 (PDE4) at a half maximal inhibitory concentration of 29 μM. The selective inhibition of the PDE4 family of enzymes affects cell signaling. Mesembrenone was the most active in inhibiting PDE4 with an IC50 value of <1 μM. Mesembrenone was 17 times more potent than mesembrine and 34 times more active than mesembrenol. The IC50 values for mesembrenone were 470 nM, followed by mesembrine at 7800 nM and mesembrenol at 10,000 nM.
Structure-Activity Relationship (SAR) studies show that cognition is likely to be selectively mediated via the long isoform of PDE-4D3. Mesembrenone alkaloids distinguish from other putative PDE-4 modulators in exhibiting concomitant serotonergic property. The serotonergic property of mesembrine alkaloids synergizes with the cAMP signal pathway in mediating the cognitive effects.
Additional actions include up-regulating vesicular monoamine transporter 2 (VMAT-2), serotonin transporter (SERT) inhibition, inhibition of phosphodiesterase 4 (PDE4) activity, anti-inflammatory properties, inhibition of monoamine oxidase A (MAO-A), and inhibition of the noradrenaline (NA) and dopamine (DA) transporters (NAT, DAT).
S. tortuosum reportedly acts as an SSRI, a PDE4 inhibitor, an acetylcholinesterase inhibitor, a CB1 receptor blocker, and a CYP17A1 inhibitor.
In an in vitro study, subfractions of S. tortuosum scavenged the free radical DPPH and inhibited acetylcholinesterase (AChE), monoamine oxidase type B (MAO-B), and glutamate NMDA receptor-mediated current, suggesting these are possible mechanisms of its neuroprotective effects. Gene ontology and docking analyses showed that molecular targets of S. tortuosum components included AChE, MAO-B, NMDA receptor subunit 2B, adenosine A2A receptor, and cannabinoid receptor 2 (CB2R).
Research on a high-mesembrine extract (Trimesemine™) found that the extract functioned as a monoamine releasing agent in addition to its serotonin reuptake inhibitory action. Mesembrine serves a primary function as a monoamine releasing agent (MRA) and secondarily as a selective serotonin reuptake inhibitor (SSRI), drug classes most commonly utilized in the treatment of anxiety and depression.
The anxiolytic properties of sceletium have been investigated in several human studies, though the body of evidence remains small and characterized by modest sample sizes.
Pharmaco-fMRI Study (Terburg et al., 2013 — PMC): In a double-blind, placebo-controlled, cross-over design, 16 healthy participants were scanned during performance in a perceptual-load and an emotion-matching task. Amygdala reactivity to fearful faces under low perceptual load conditions was attenuated after a single 25 mg dose of Zembrin. Follow-up connectivity analysis on the emotion-matching task showed that amygdala–hypothalamus coupling was also reduced. These results demonstrated, for the first time, the attenuating effects of S. tortuosum on the threat circuitry of the human brain, providing supporting evidence that the dual 5-HT reuptake inhibition and PDE4 inhibition of this extract might have anxiolytic potential by attenuating subcortical threat responsivity.
Reay et al. (2020) — Human Psychopharmacology: To investigate the anxiolytic properties of a standardized extract of Sceletium tortuosum (Zembrin®), two studies utilized a placebo-controlled, double-blind, between-subject experimental design to investigate the effects of a single dose of Sceletium tortuosum (25 mg, Zembrin®) on laboratory stress/anxiety responding in 20 young healthy volunteers. To elicit feelings of stress/anxiety, participants completed 20 minutes of the multitasking framework in study 1 and a 5-minute simulated public speaking task in study 2. A series of analyses of covariances revealed no treatment effect in study 1; however, study 2 revealed subjective anxiety levels to be significantly lower in the Zembrin® group at the prestress induction point and a significant interaction between treatment and time on heart rate. Taken together, results indicate that a single dose of Zembrin® can ameliorate laboratory stress/anxiety responding in healthy volunteers. The authors conclude this as the first tentative behavioral evidence to support the anxiolytic properties of Sceletium tortuosum (25 mg Zembrin®).
Evidence Strength: Preliminary. Results are mixed across two sub-studies, sample sizes are small (n=20 per study), populations were healthy volunteers rather than clinical anxiety patients, and the treatment was a single acute dose. The authors themselves characterized the results as "tentative."
Two clinical trials, both using the proprietary extract Zembrin, have examined cognitive outcomes.
Chiu et al. (2014) — Proof-of-Concept RCT (PMC4217361): In this registered trial (ClinicalTrials.gov NCT01805518), 21 subjects (mean age: 54.6 years ±6.0 years; male/female ratio: 9/12) entered the study. Zembrin at 25 mg daily dosage significantly improved cognitive set flexibility (P < 0.032) and executive function (P < 0.022), compared with the placebo group. Positive changes in mood and sleep were found. Zembrin was well tolerated. The cognitive-enhancing effects of Zembrin were considered to likely implicate the PDE-4-cAMP-CREB cascade, a novel drug target in the potential treatment of early Alzheimer's dementia.
Hoffman et al. (2020) — RCT in Young Adults: In a randomized placebo-controlled trial of 60 physically active men and women aged 20–35, Sceletium tortuosum extract (Zembrin) treatment (25 mg, once daily, orally) for eight days significantly improved complex reactive performance (requiring responses to repeated visual stimuli with a cognitive load) compared with placebo. The extract was also associated with significantly higher reactive agility compared to placebo in a task that required decision making. However, no significant differences between Sceletium tortuosum extract and placebo groups were observed for visual tracking performance, motor reaction time, visual reaction time, or physical reaction time.
No clinical trials have tested whether Sceletium tortuosum can prevent dementia or age-related cognitive decline. Only two studies have tested the effects of Sceletium tortuosum on cognitive functions — one in young adults and the other in middle-aged adults — and no studies have tested Sceletium tortuosum in older adults with cognitive symptoms.
Evidence Strength: Preliminary. The two existing RCTs are small, short in duration, restricted to healthy volunteers, and use only one proprietary extract (Zembrin). Findings point to possible benefit for specific aspects of complex cognition and executive function, but findings did not extend uniformly to all cognitive domains tested.
Over the past decade, the plant has attracted increasing attention for its possible applications in promoting a sense of wellbeing and relieving stress in healthy individuals and for treating clinical anxiety and depression. The activity of the Sceletium tortuosum extract on the 5-HT transporter and PDE4 may explain the clinical effects of preparations made from this plant. These activities relate to the presence of alkaloids, particularly mesembrine and mesembrenone.
The Chiu et al. (2014) trial additionally noted positive changes in mood and subjective quality of sleep and sleep onset compared to placebo. However, to date, no large-scale, adequately powered randomized controlled trials have examined the antidepressant efficacy of any sceletium preparation in patients diagnosed with major depressive disorder. Clinical and preclinical (in vivo and in vitro) studies have supported the antidepressant properties of sceletium, but the lack of studies in patients diagnosed with MDD has increased the need for validated animal models to provide translational evidence.
Evidence Strength: Weak for clinical depression. Mechanistic evidence (SSRI and PDE4 activity) is strong in vitro, and animal models have shown antidepressant-like effects, but no clinical trials in diagnosed depressed patient populations have been published as of the available literature.
Bennett et al. (2018) determined the cytoprotective and anti-inflammatory effects of two S. tortuosum extracts varying in alkaloid composition (high mesembrine and high delta7-mesembrenone extracts) in delaying chronic disease progression. The extracts were evaluated on human astrocytes viability basally and in the presence of an acute pro-inflammatory stimulus (lipopolysaccharide [LPS]) using the XTT assay and cytokine measurement. The results showed that the high-mesembrine extract demonstrated anti-inflammatory and cytoprotective effects, while the polyphenols-rich delta7-mesembrenone extract showed potent antioxidant activity. Both extracts showed mild neuroprotective effects as indicated by inhibition of acetylcholinesterase and tyrosinase enzymes.
An electropharmacogram of Zembrin showed dose-dependent cognitive function enhancement in adult Fischer rats. Studies also showed beneficial effects of S. tortuosum in dogs with clinically diagnosed dementia.
The cognitive-enhancing effects of Zembrin are considered to likely implicate the PDE-4-cAMP-CREB cascade, a novel drug target in the potential treatment of early Alzheimer's dementia.
Evidence Strength: In vitro and animal/preclinical only. No clinical trials have tested the efficacy of S. tortuosum in people with dementia.
The high-mesembrine Sceletium extract exerted cytoprotective and anti-inflammatory effects in human astrocyte cell models. In contrast, the high delta7-mesembrenone extract, rich in polyphenols, exhibited potent antioxidant effect, although with relatively higher risk of adverse effects with overdose in vitro.
The crude extracts and commercially available standardized extracts of S. tortuosum have displayed a wide spectrum of biological activities — including antimalarial, anti-oxidant, immunomodulatory, anti-HIV, neuroprotection, and enhancement of cognitive function — in in vitro or in vivo studies.
Evidence Strength: Preclinical only. All anti-inflammatory and antioxidant data come from in vitro cell studies. No human trials have evaluated these endpoints.
The most rigorous safety data for sceletium derive from two formal programs, one preclinical and one clinical.
Murbach et al. (2014) — Rat Toxicology: Murbach et al. assessed the toxicological safety of Zembrin® in a 14-day repeated oral toxicity study in specific pathogen-free male and female Crl Wistar rats using five different daily doses (0, 250, 750, 2500, and 5000 mg/kg body weight/day). Additionally, a 90-day subchronic repeated oral toxicity assessment was conducted using lower doses of Zembrin® (0, 100, 300, 450, and 600 mg/kg bw/day). Different parameters including rearing behaviour, locomotion, spatial parameters, and turning behaviour were evaluated in the final study week. Neither mortality nor treatment adverse effects were observed in experimental animals in the 14- and 90-day studies.
Nell et al. (2013) — Three-Month Human RCT: The objective of this study was to evaluate the safety and tolerability of two doses (8 mg and 25 mg once daily) of a 2:1 standardized extract of Sceletium tortuosum (Zembrin®) in healthy adult volunteers over a three-month period, using a randomized, double-blind, parallel-group, placebo-controlled single center design. There were no apparent differences between the three treatments with regard to vital signs, 12-lead ECG, body weight, and physical examination from screening to the end of the 3-month treatment period. No significant changes were observed in hematology or biochemistry parameters between initial screening and the end of the study. No significant effects of the Sceletium tortuosum extract were seen on vital signs, electrocardiograms, body weight, physical examination, or hematology and biochemistry parameters. The most commonly reported adverse event in the trial was headache, which had a higher incidence with placebo than with the extract.
Clinical studies evaluating potential CNS effects have used 25 mg (either as a single dose or once daily, with treatment durations ranging from 8 days to 9 weeks) of a proprietary extract of S. tortuosum (standardized to a total alkaloid content for the four main Sceletium alkaloids [mesembrenone, mesembrenol, mesembrine, and mesembranol] of 0.4%).
Published clinical evidence is lacking to provide standardized dosing recommendations beyond the doses used in existing trials.
Clinically, S. tortuosum shows a relatively low side-effect profile, although elevated blood pressure, headache, nausea, irritability, insomnia, and anxiety are associated with its use. Some subjects taking the extract in clinical trials reported transient gastrointestinal discomfort. In the three-month safety RCT, headache was the most commonly reported adverse event but occurred at higher incidence in the placebo group than in either active treatment group.
Zembrin®, in male and female Crl:(WI)BR Wistar rats, showed no mortality or treatment-related adverse effects spanning 14 or 90 days with doses of 600 mg/kg bw/day and 5,000 mg/kg bw/day, respectively. Early toxicology studies, including animal tests, suggest it is generally safe at standard doses with few reported side effects, though long-term effects and drug interactions — particularly with serotonin-affecting medications — need further study.
There are no reports to date of herb-drug interactions with Sceletium tortuosum. However, based on its mechanisms of action, it should not be used with drugs known to alter serotonin uptake or release. Concurrent use with other SSRI antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or serotonergic drugs represents a theoretical risk of serotonin syndrome based on pharmacological mechanism, though this has not been formally documented in published case reports from available literature.
One concern involves mesembrine's strong effects on the serotonin system, which could raise the risk of misuse, particularly among individuals prone to abusing psychoactive substances. However, preclinical studies suggest that extracts of Sceletium tortuosum, including mesembrine, show no reinforcing effects in rodents, indicating a low likelihood of abuse.
The genotoxic safety of the extract Zembrin® of the medicinal plant S. tortuosum was formally evaluated according to OECD Genotoxicity Guidelines 471, 487, and 474. These assessments, conducted using standardized OECD protocols, did not identify genotoxic signals in the research program accompanying the Murbach et al. (2014) toxicology publication.
Despite growing scientific interest in mesembrine's pharmacological mechanisms, particularly its role as a serotonin reuptake inhibitor, surprisingly little is known about its toxicological profile. Fundamental data on toxicity remain largely absent, highlighting a significant gap in basic research. At present, little to no pharmacological information is available in terms of the molecular physiological effects of mesembrine alkaloids in medical clinical settings.
A few small, short-duration clinical trials have suggested that Sceletium tortuosum extracts may improve some complex cognitive functions; however, evidence from large, long-term studies is lacking.
Owing to its pharmacological activities, S. tortuosum was first cultivated commercially in 1996 by Grassroots Natural Products under contract to the phytomedicines program of a South African pharmaceutical company, Pharmacare Ltd. The plant and its extracts are sold as dietary supplements or functional food ingredients in multiple markets. Inadvertent regulatory favoritism combined with the lack of means for adequate protection of intellectual property may obstruct innovation by creating economic barriers for the successful introduction of botanicals from developing countries into most of the world's health product markets.
Health conditions that Sceletium may help support.
Mesembrine-type alkaloids have been flagged in the peer-reviewed pharmacology literature as showing promise for addiction disorders, linked to CB1 receptor blockade and absence of conditioned place preference in animal models. Traditional healers have used it to reduce cravings. No clinical trial in human addiction patients has been completed.
Phytochemical analysis confirms sceletium extracts contain polyphenols, tannins, and other antioxidant compounds showing free-radical scavenging activity in vitro. A high delta7-mesembrenone extract demonstrated potent antioxidant effects. Evidence is exclusively preclinical.
Multiple human studies support sceletium's anxiolytic potential. A pharmaco-fMRI RCT (n=16) showed a single 25 mg dose of Zembrin® attenuated amygdala reactivity to fearful stimuli and reduced amygdala-hypothalamus coupling. A 2020 placebo-controlled study found 25 mg Zembrin® significantly lowered subjective anxiety and blunted heart-rate response during a stress task. A 2023 systematic review/meta-analysis of four RCTs (n=117) found mixed pooled results, with no statistically significant group-level reduction in anxiety scores overall.
Sceletium has documented calming effects underpinned by serotonergic and PDE4-inhibiting mechanisms. Clinical studies show attenuation of stress-linked arousal responses in healthy adults. Traditionally, San and Khoikhoi peoples used it as a tranquilizer and mood-elevator, effects now partially corroborated in human pharmacological work.
In vitro and animal studies show sceletium alkaloids, particularly mesembrine, exert cytoprotective and mild anti-inflammatory effects, modulating IL-6 and MCP-1 cytokines and reducing inflammatory markers. Inhibition of adrenal glucocorticoid synthesis via CYP17A1 provides a further anti-inflammatory dimension. Evidence remains preclinical.
Preclinical rodent studies demonstrate analgesic properties of mesembrine in nociception assays without abuse liability or ataxia. Traditional use as an analgesic and painkiller by San and Khoikhoi peoples is well-documented. No human clinical trial has been conducted for chronic pain as a primary endpoint.
The Chiu et al. (2014) proof-of-concept RCT in healthy older adults specifically framed sceletium's PDE4-inhibiting cognitive benefits in the context of Alzheimer's disease risk. Network pharmacology analysis identified overlapping targets with neurodegenerative pathways. Early clinical results are promising but trial scale is small.
Sceletium's multi-modal pharmacology—SERT inhibition, PDE4 inhibition, MAO-A inhibition, and VMAT-2 upregulation—positions it mechanistically as an antidepressant. Pre-clinical rodent models show antidepressant-like activity comparable to escitalopram. A small proof-of-concept RCT in healthy older adults found improvements in mood alongside cognitive gains. Human clinical trials specifically in diagnosed depression patients remain sparse.
By dampening threat-circuit reactivity in the amygdala and supporting serotonergic and PDE4-mediated neurotransmission, sceletium may underpin emotional resilience. Clinical data show mood stabilization alongside cognitive gains in healthy older adults. Traditionally it was used as a mood-elevator and emotional stabilizer across many contexts.
Clinical trials show sceletium can improve complex, cognitively loaded performance tasks. The Chiu et al. (2014) RCT found improved cognitive set flexibility and executive function at 25 mg Zembrin® daily in healthy older adults. A separate RCT of physically active adults found improved complex reactive performance and reactive agility requiring decision-making, though simpler reaction-time tasks were unaffected.
Sceletium's mesembrine-rich extracts have been shown in vitro and in preclinical models to target adrenal CYP17A1 and other steroidogenic enzymes, reducing glucocorticoid synthesis. Animal data also indicate modulation of HPA-related cytokines and corticosterone under stress. These findings are preclinical; human HPA endpoint trials are underway.
PDE4 inhibition by sceletium's alkaloids activates the cAMP-CREB signaling cascade linked to synaptic plasticity and memory consolidation. Clinical data from the Chiu et al. (2014) RCT demonstrated improved cognitive flexibility and executive function. Traditionally, the plant was said to facilitate clarity of thought and removal of distracting mental noise.
The PDE4-cAMP-CREB pathway targeted by sceletium's alkaloids is directly implicated in memory consolidation and recall. A proof-of-concept RCT in healthy older adults reported positive cognitive outcomes including memory-related parameters. Sceletium has a documented traditional reputation for enhancing mental performance, including memory.
Sceletium's alkaloids modulate multiple neurotransmitter systems: inhibiting serotonin reuptake (SERT), upregulating VMAT-2 to enhance monoamine vesicular release, mildly inhibiting MAO-A and AChE, inhibiting PDE4, and blocking CB1 receptors. This multi-target profile is well characterized pharmacologically.
Sceletium's attenuation of the amygdala-hypothalamus threat circuit—demonstrated by pharmaco-fMRI—is directly relevant to panic and overwhelm, which involve hyperactivation of this same circuitry. The anxiolytic effect on subjective stress and heart rate during laboratory stress induction provides behavioral corroboration.
Sceletium's serotonergic mechanism—SERT inhibition and monoamine release—is directly relevant to seasonal affective disorder (SAD), which is treated clinically with SSRIs and light therapy. No clinical trial has specifically evaluated sceletium in SAD patients, but the mechanistic parallel with established SAD pharmacotherapy supports this link.
The Chiu et al. (2014) proof-of-concept RCT found positive changes in sleep alongside cognitive improvements in healthy older adults receiving 25 mg Zembrin® daily for three weeks. Traditional use of sceletium as a sedative/soporific in children is also well-documented ethnobotanically.
Human and animal data support sceletium's capacity to attenuate acute physiological and psychological stress responses. The 2020 Reay et al. RCT demonstrated reduced heart rate and subjective stress during laboratory stress induction with 25 mg Zembrin®. Traditionally, the plant was consumed by San hunters specifically to reduce stress during demanding activities.
Relief of abdominal pain is one of sceletium's most consistently documented traditional uses, recorded in multiple ethnobotanical and pharmacopeial sources. San and Khoikhoi peoples chewed the plant for this purpose. No clinical trial has specifically evaluated this indication.
San and Khoikhoi hunter-gatherers traditionally used sceletium to suppress hunger and thirst during long hunts. This is recorded across multiple ethnobotanical sources and peer-reviewed ethnopharmacology reviews. No clinical trial has formally evaluated appetite suppression.
San and Khoikhoi peoples historically used sceletium to fight fatigue and maintain physical and mental performance during demanding activities. This is well-documented in ethnobotanical literature. Clinical trial data on alertness as a primary endpoint are absent, and one RCT found no effect on subjective energy or alertness measures.
San and Khoikhoi hunter-gatherers documented used sceletium to sustain physical performance and endurance during extended hunts. A small RCT (Hoffman et al., 2020) in recreationally trained adults found improvements in complex reactive performance but no effect on physical reaction time, motor reaction time, or physical performance metrics.
Sceletium has an ethnobotanically documented history of use as a soporific. Historical records from 1898 describe fresh sceletium juice being given to young children to rapidly induce deep sleep. The sedative/hypnotic property is one of the plant's traditional roles, but no clinical trial has specifically measured sleep latency as a primary endpoint.
Chewing sceletium leaves to relieve toothache is one of the most consistently documented traditional uses across multiple independent historical and ethnopharmacological sources spanning centuries. No clinical trial has evaluated this specific application.
Body systems that Sceletium may help support.
Go back